These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 14581346)

  • 1. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
    Higuchi T; Iwama T; Yoshinaga K; Toyooka M; Taketo MM; Sugihara K
    Clin Cancer Res; 2003 Oct; 9(13):4756-60. PubMed ID: 14581346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
    Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
    N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
    Ehrich EW; Schnitzer TJ; McIlwain H; Levy R; Wolfe F; Weisman M; Zeng Q; Morrison B; Bolognese J; Seidenberg B; Gertz BJ
    J Rheumatol; 1999 Nov; 26(11):2438-47. PubMed ID: 10555907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial.
    Morrison BW; Christensen S; Yuan W; Brown J; Amlani S; Seidenberg B
    Clin Ther; 1999 Jun; 21(6):943-53. PubMed ID: 10440619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
    Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
    Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
    Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
    N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of oral rofecoxib versus intravenous ketoprofen as an adjuvant to PCA morphine after urologic surgery.
    Cabrera MC; Schmied S; Derderian T; White PF; Vega R; Santelices E; Verdugo F
    Acta Anaesthesiol Scand; 2004 Oct; 48(9):1190-3. PubMed ID: 15352968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
    Michael Hill C; Sindet-Pederson S; Seymour RA; Hawkesford JE; Coulthard P; Lamey PJ; Gerry Cowan C; Wickens M; Jeppsson L; Dean AD; Svensson O
    Clin Ther; 2006 Sep; 28(9):1279-95. PubMed ID: 17062301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.
    Katz N; Ju WD; Krupa DA; Sperling RS; Bozalis Rodgers D; Gertz BJ; Gimbel J; Coleman S; Fisher C; Nabizadeh S; Borenstein D;
    Spine (Phila Pa 1976); 2003 May; 28(9):851-8; discussion 859. PubMed ID: 12941996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups.
    van Adelsberg J; Gann P; Ko AT; Damber JE; Logothetis C; Marberger M; Schmitz-Drager BJ; Tubaro A; Harms CJ; Roehrborn C
    Curr Med Res Opin; 2007 Sep; 23(9):2063-70. PubMed ID: 17651539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer.
    Evans JF
    Am J Clin Oncol; 2003 Aug; 26(4):S62-5. PubMed ID: 12902858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.
    Hawkey C; Laine L; Simon T; Beaulieu A; Maldonado-Cocco J; Acevedo E; Shahane A; Quan H; Bolognese J; Mortensen E
    Arthritis Rheum; 2000 Feb; 43(2):370-7. PubMed ID: 10693877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies.
    Daniels SE; Desjardins PJ; Bird SR; Smugar SS; Tershakovec AM
    Clin Ther; 2006 Jul; 28(7):1022-34. PubMed ID: 16990080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
    Gibofsky A; Williams GW; McKenna F; Fort JG
    Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial.
    Buvanendran A; Kroin JS; Tuman KJ; Lubenow TR; Elmofty D; Moric M; Rosenberg AG
    JAMA; 2003 Nov; 290(18):2411-8. PubMed ID: 14612477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
    Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
    Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.
    Schwartz JI; Chan CC; Mukhopadhyay S; McBride KJ; Jones TM; Adcock S; Moritz C; Hedges J; Grasing K; Dobratz D; Cohen RA; Davidson MH; Bachmann KA; Gertz BJ
    Clin Pharmacol Ther; 1999 Jun; 65(6):653-60. PubMed ID: 10391671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
    Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
    Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.